Bourgeon Capital Management LLC Lowers Holdings in Becton Dickinson and Co (BDX)

Bourgeon Capital Management LLC lowered its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 3.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 28,962 shares of the medical instruments supplier’s stock after selling 1,085 shares during the quarter. Becton Dickinson and makes up 3.4% of Bourgeon Capital Management LLC’s holdings, making the stock its 8th largest position. Bourgeon Capital Management LLC’s holdings in Becton Dickinson and were worth $6,200,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. Pathstone Family Office LLC boosted its position in Becton Dickinson and by 0.4% during the second quarter. Pathstone Family Office LLC now owns 3,974 shares of the medical instruments supplier’s stock worth $2,530,000 after purchasing an additional 15 shares in the last quarter. Dorsey & Whitney Trust CO LLC boosted its position in Becton Dickinson and by 1.5% during the second quarter. Dorsey & Whitney Trust CO LLC now owns 1,675 shares of the medical instruments supplier’s stock worth $327,000 after purchasing an additional 25 shares in the last quarter. Sii Investments Inc. WI boosted its position in Becton Dickinson and by 2.2% during the second quarter. Sii Investments Inc. WI now owns 1,738 shares of the medical instruments supplier’s stock worth $342,000 after purchasing an additional 38 shares in the last quarter. Quadrant Capital Group LLC boosted its position in Becton Dickinson and by 0.5% during the second quarter. Quadrant Capital Group LLC now owns 9,960 shares of the medical instruments supplier’s stock worth $1,925,000 after purchasing an additional 45 shares in the last quarter. Finally, WFG Advisors LP boosted its position in Becton Dickinson and by 0.9% during the second quarter. WFG Advisors LP now owns 5,376 shares of the medical instruments supplier’s stock worth $1,049,000 after purchasing an additional 48 shares in the last quarter. Institutional investors own 75.68% of the company’s stock.

A number of equities analysts have issued reports on BDX shares. Zacks Investment Research upgraded Becton Dickinson and from a “hold” rating to a “buy” rating and set a $240.00 price target on the stock in a research report on Wednesday, January 3rd. Deutsche Bank set a $260.00 price target on Becton Dickinson and and gave the stock a “buy” rating in a research report on Friday, December 29th. Argus increased their price target on Becton Dickinson and to $235.00 and gave the stock a “buy” rating in a research report on Thursday, December 14th. They noted that the move was a valuation call. Stifel Nicolaus reiterated a “buy” rating and set a $245.00 price target on shares of Becton Dickinson and in a research report on Friday, November 3rd. Finally, Bank of America reiterated a “buy” rating and set a $260.00 price target on shares of Becton Dickinson and in a research report on Friday, January 19th. Four investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. Becton Dickinson and currently has a consensus rating of “Buy” and a consensus target price of $237.27.

Becton Dickinson and Co (NYSE:BDX) opened at $221.92 on Thursday. The firm has a market capitalization of $50,910.00, a P/E ratio of 169.40, a PEG ratio of 1.60 and a beta of 1.12. Becton Dickinson and Co has a 1 year low of $175.66 and a 1 year high of $248.39. The company has a debt-to-equity ratio of 1.44, a current ratio of 5.58 and a quick ratio of 5.03.

Becton Dickinson and (NYSE:BDX) last released its earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share for the quarter, beating the consensus estimate of $2.41 by $0.07. The business had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $3.05 billion. Becton Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the business posted $2.33 earnings per share. sell-side analysts expect that Becton Dickinson and Co will post 10.92 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, March 30th. Stockholders of record on Friday, March 9th will be given a $0.75 dividend. The ex-dividend date is Thursday, March 8th. This represents a $3.00 annualized dividend and a dividend yield of 1.35%. Becton Dickinson and’s dividend payout ratio (DPR) is presently 229.01%.

WARNING: “Bourgeon Capital Management LLC Lowers Holdings in Becton Dickinson and Co (BDX)” was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://sportsperspectives.com/2018/02/08/bourgeon-capital-management-llc-lowers-holdings-in-becton-dickinson-and-co-bdx.html.

About Becton Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply